Diabetic kidney disease (DKD) affects millions of Americans and is the leading cause of end stage renal disease (ESRD). Several promising agents such as Reata’s bardoxolone have failed to succeed in clinical trials. Physicians routinely place the need for new drugs to treat this condition as a high priority and there are several late stage clinical trials in process.
Market Dynamix™: Diabetic Kidney Disease (US) combines qualitative feedback from leading opinion leaders and other stakeholders with large scale quantitative feedback of “in the trenches” nephrologists, endocrinologists, cardiologists, and PCPs.
Qualitative interviews with peer-nominated DKD KOLs (n=5) will describe the new therapies on the horizon and their perspective on where each will have an advantage. Additional interviews with nephrologists (n=5), endocrinologists (n=5), cardiologists (n=5) and PCPs (n=5) give real world perspective on the challenge of managing this condition.
An on-line quantitative survey of more than 300 nephrologists, endocrinologists, cardiologists, and PCPs addresses patient load, referral and co-management issues, current treatment approaches with an in-depth assessment of the approval of INVOKANA and use of other SGLT2s, unmet needs and reaction to pipeline product profiles. This is the third annual report published on this topic; prior reports were published in 2016 and 2018.
Learn more about Market Dynamix™ reports here.
- What is the comparative level of unmet need for new products to treat diabetic kidney disease?
- How do physicians assess DKD and what do referral patterns look like between PCPs, endocrinologists, cardiologists and nephrologists? Which lab tests and target levels are used to guide treatment and referral decisions?
- Which medications are used in an attempt to slow DKD and how sat-isfied are physicians with these treatments? Do physicians preferentially use canagliflozin (and/or other SGLT2 inhibitors) in patients with DKD on the basis of its newly minted DKD indication?
- Regarding new treatments, what is the level of unmet need? What products and MOAs are physicians aware of? What unique features are most appealing and most worrisome? Which clinical trial endpoints will be most important for new agents?
- How do physicians respond to pipeline product profiles for finerenone, CCX140/CCR2, bardoxolone methyl, praliciguat, selonsertib, nidufexor, STEGLUJAN, SEGLUROMET, and Neo-Kidney Augment?
Combo agents: STEGLUJAN, SEGLUROMET
bardoxolone methyl, finerenone, CCX140/CCR2, nidufexor, selonsertib, praliciguat, Neo-Kidney Augment